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1. Abstract 
 
Background:  
Peripheral arterial disease (PAD) may interfere with the assessment of pulse wave 
velocity (PWV) due to atherosclerotic lesions along the arterial tree.  
Aim: To evaluate the effect of percutaneous transluminal angioplasty (PTA) of the 
lower limb on pulse wave velocity in patients with PAD. 
Methods:  
Pulse wave velocity (PWV) was measured prior and after lower limb angioplasty in 
patients with PAD. Aortic PWV was assessed with the Mobil-O-Graph (ABPM by 
IEM; Stolberg, Germany) derived from the brachial artery (aPWV) using a brachial 
cuff-based method. In addition, PWV was assessed with an oscillometric technique 
(Vicorder system SMT Medical, Würzburg, Germany) for the carotid-femoral (cfPWV) 
and femoro-tibial (ftPWV) segments in both limbs. Periinterventional changes were 
analysed by the Wilcoxon signed rank test. 
Results:  
Overall 58 patients were treated with angioplasty for Rutherford stage 2-5 with 
bilateral treatment in four patients. Treated limbs (n=62) were compared with control 
limbs (n=54). In the PTA-limbs, the ftPWV and the ankle-brachial arterial pressure 
index improved both from 7.6±2.5m/s to 9.2±2.3m/s (p<0.0001) and from 0.67±0.32 
to 0.86±0.28 (p<0.0001), respectively. In the untreated limbs, ftPWV remained 
unchanged (9.1±2.7 m/sec and 9.2±2.6 m/sec, p=0.334). No significant changes 
were observed for the cfPWV for both the control-limb (8.6±2.5 m/s and 8.4±2.2m/s 
at follow-up, p=0.744) and the PTA–limb (8.2±2.2 m/s and 8.3±2 m/s at follow-up, 
p=0.116). Likewise, aPWV remained unchanged with 11.6± 2.7m/s and 11.5± 2.6m/s 
(p=0.410). 
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Conclusion:  
Lower limb angioplasty in peripheral arterial disease leads to an increase in pulse 
wave velocity in the treated segments. This indicates that peripheral arterial 
obstructions lower PWV in the muscular-arterial segments. In contrast, lower limb 
angioplasty does not affect aortic and cfPWV.  
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2. Introduction 
 
Arterial stiffness is an independent predictor of survival [1]. There are several non-
invasive methods for assessment that are easily applied in clinical routine [1].  
The gold standard for assessment of arterial stiffness is carotid-femoral pulse 
wave velocity (PWV), but other devices that assess brachial-ankle PWV are also 
frequently used [2]. 
Current guidelines of the European Societies of Hypertension and Cardiology 
recommend measurement of PWV in patients at intermediate risk for risk stratification 
and suggest a cut-off value for carotid femoral PWV of 10m/sec for arterial organ 
damage [3,4,5,6]. An increase in PWV of 1m/sec is associated with a 7% elevated 
risk for cardiovascular events in a 60-year-old man without cardiovascular risk factors 
[4].  
The ankle brachial arterial pressures index (ABI) is an established vascular 
marker for the diagnosis of peripheral arterial disease (PAD) and is an independent 
predictor of cardiovascular events [7]. PAD affects more than 20% of the elderly 
population and prognosis in these patients is poor due to cardiovascular and cerebral 
events [7]. Furthermore, ABI reflects atherosclerosis along the arterial tree, and the 
degree of impairment correlates with a risk of all-cause and cardiovascular mortality 
[7]. 
Hence, ABI and PWV are both vascular markers, whereby ABI reflects 
peripheral arterial obstruction and carotid-femoral PWV stiffening of the aorta due to 
ageing (sclerosis) or atheroma (atherosis) [8]. In the Rotterdam study, PAD was 
associated with an increased carotid-femoral PWV [9]. Similarly, Catalano et al. 
found elevated PWV in PAD when using applanation tonometry [10]. In contrast, a 
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reduced brachial-ankle pulse wave velocity with lower ABI was found and 
improvement of both following angioplasty was reported [11].  
To our knowledge so far, there is no data on the effect of percutaneous 
transluminal angioplasty (PTA) on both elastic and muscular arteries assessed as 
PWV. We hypothesized that PTA affects the PWV of the treated segments, i.e. 
carotid-femoral or femoro-tibial but not the aortic PWV.  
Therefore, we evaluated the impact of PTA on carotid-femoral (cfPWV), 
femoral-tibial (ftPWV) and brachial-derived aortic PWV (aPWV) in patients with PAD. 
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3. Patients and Methods 
 
3.1. Study design and patient selection  
The study was conducted at a tertiary referral centre as a prospective single-
centre evaluation of patients with PAD referred for PTA. The following data were 
collected for all patients: medical history, brachial systolic and diastolic blood 
pressures, heart rate, body mass index (weight/height²), cardiovascular risk factors 
(arterial hypertension, diabetes mellitus, dyslipidemia, smoking, family history), 
comorbidities, medication, ankle-brachial index and pulse wave analysis as described 
below.  
Patients continued to take their regular medication. Coronary and 
cerebrovascular diseases were defined for the purposes of this study by clinical 
history of either events or interventions. The glomerular filtration rate was estimated 
by Cockcroft-Gault equation on the basis of serum creatinine levels according to 
K/DOQI clinical practice guideline [12]. Participants were categorized as currently 
smoking, stopped smoking less than one year or more than one year ago. 
Dyslipidemia was defined by a total HDL- cholesterol ratio above 5 mmol/l or the use 
of lipid-lowering medications. Patients were classified as diabetics if their HbA1c was 
6.5% and/or their serum glucose level were ≥7.00 mmol/L, if their physician had 
diagnosed them and/or if they were treated medically. Patients were considered 
hypertensive if brachial systolic blood pressure (SBP) was above 140 mmHg or 
brachial diastolic blood pressure (DBP) was above 90 mmHg or if they were on 
antihypertensive medications.  
Only patients with chronic and stable PAD were eligible for the study. PAD 
was defined by ankle-brachial arterial pressure index (ABI) of < 0.9.  Patients were 
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assigned in Rutherford stages according to medical history. Exclusion criteria were 
cardiac arrhythmia and chronic inflammatory vascular disorders.  
The measurements of pulse wave velocity were performed before and after 
PTA with two different non-invasive methods: a brachial cuff-based method using the 
Mobil-O-Graph (IEM, Stolberg, Germany) which derives an estimation of aortic PWV 
(aPWV) from pressure waveforms recorded at the brachial artery and second carotid-
femoral and femoro-tibial PWV were recorded using the Vicorder (SMT Medical, 
Würzburg, Germany) device, which detected transit time from cuffs placed around 
the neck, thigh and ankle [13,14,15,16,17,18,19]. All measurements were made by a 
single trained physician and a study nurse. The treatments and investigations were 
part of the standard of care. The study was approved by the ethical committee (2013-
0575) and all patients had given written informed consent for procedure and 
evaluation of data. 
 
3.2. Assessment of Hemodynamics and Arterial Stiffness 
Patients were studied in supine position after 10 minutes of rest in a quiet 
room. SBP and DBP were measured three times in the right and left arm. The 
average of the last two measurements was recorded as representative of brachial 
blood pressure and the Mobil-O-Graph placed on the arm with the higher systolic 
blood pressure for further assessment.  
Instantaneously, after brachial blood pressure estimation at least three 
measurements of carotid-femoral and femoral-tibial pulse wave velocity were 
obtained with the Vicorder and the mean value was used for analysis of each 
participant. While the carotid-femoral and the femoral-tibial pulse wave velocity with 
the Vicorder were performed, the Mobil-O-Graph measurements were recorded 
simultaneously.  
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3.3. Mobil-O-Graph 
 
The Mobil-O-Graph (IEM, Stolberg, Germany) suggested by ARCSolver is 
based on an oscillometric method for assessment of pulse wave velocity via 
recording of blood pressure with a common cuff placed over A. brachialis. The 
diastolic blood pressure level is therefore measured for approximately 10 seconds 
with the conventional cuff and a MPX5050 pressure sensor (Freescale Inc., Tempe, 
AZ, USA). After digitalization, the single obtained pressure waves are verified for their 
plausibility, using pulse wave analysis and impedance wave separation. Thereafter 
they are compared with each other to detect artefacts and finally an aortic pulse wave 
is induced via general transfer function [13,14,15]. This operator-independent method 
was invasively validated by Hametner et al. for 24-hour ambulatory blood pressure 
and aortic PWV monitoring [16]. 
 
3.4. Vicorder 
The Vicorder (SMT Medical, Würzburg, Germany) is an oscillometric method 
to record the carotid to femoral and femoral to tibial pulse wave velocity. First, a neck 
pad is placed other the patient’s neck with a partial inflatable 30-mm 
plethysmographic sensor positioned over the carotid artery, able to record the carotid 
pulse wave [17]. A second 100-mm wide blood pressure cuff is placed around the 
upper thigh to obtain the femoral pulse wave [17]. 
Both cuffs are inflated to about 60 mmHg and waveforms of the carotid and 
femoral artery are recorded simultaneously over about 10 consecutive heartbeats to 
estimate transit time [17]. The beginning of the systole is identified by an inbuilt foot-
to-foot algorithm that is centred around the peak of the second derivative of pressure 
[17].  
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The path length was defined, as advised by the manufacturer and Hickson and 
colleagues, by direct measurement between the suprasternal notch to the top of the 
thigh cuff [17,18,19].  
Carotid-femoral PWV velocities were calculated as path length divided by the 
transit time: cfPWV (m/s) = D (path length)/∆T(transit time) [17,19]. The 
measurements of femoral to pedal velocities were taken similarly placing the proximal 
collar on the right/left upper thigh and the distal cuff respectively over the right/left 
ankle. The path length was defined between the top of the thigh and the top of the 
ankle cuff.  
 
3.5. Ankle-Brachial Arterial Pressure Index Assessment 
Ankle-brachial pressure index assessments were performed as part of the 
standard procedure. Systolic blood pressures were measured in both arms and in 
posterior tibial (PT), peroneal (P) and dorsal pedal (DP) arteries of both limbs using 
appropriate-sized cuffs and a hand–held 6-MHz Doppler probe (Kranzbühler, 
Logidop 2, Pilger Medical Electronics, Switzerland). The ABI was than calculated for 
each leg separately with the highest systolic blood pressure of the PT, P or DP 
divided by the highest brachial systolic pressures. 
 
3.6. Statistical Analysis 
Descriptive statistics for continuous variables are given as mean ± standard 
deviation. For categorical variables, results are presented as frequency and 
percentage. Periinterventional changes were analysed by the Wilcoxon signed rank 
test. Differences between carotid-femoral PWV and aortic PWV were compared by 
Mann Whitney U-Test.  
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All data were analyzed using the IBM SPSS software Version 22.0 statistical package 
for Windows (SPSS Inc. Armonk, NY: IBM Corp.).  A value of p<0.05 was considered 
significant.  
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4. Results 
 
Between January and April 2014, 63 patients fulfilled the clinical selection 
criteria of which 5 patients were excluded because of invalid readings of pulse 
volume recordings resulting in 58 patients finally analysed. Lesion localisations and 
characteristics are summarised in Figure 1. In all 58 patients aPWV were assessed 
per patient whereas ABI and cf- and ft-PWV were assessed per limb resulting in 115 
limbs (1 below the knee amputation) evaluated either as control-limbs (n=53) or PTA-
limbs (n=62).  
The baseline characteristics of the study population are presented in Table 1.  
Mean age was 73.7±13 years and 44.8% (n=26) were female. In 57% (n=33) 
intermittent claudication (Rutherford 2 and 3) was the main complaint and 43% 
(n=25) had either rest pain or tissue lesions (Rutherford 4 and 5).  
The majority of the treated lesions were located unilaterally (87%) and in the 
femoro-popliteal segments (53%). Only few lesions were located in the iliac (29%) 
and below-the-knee segments (18%). 
 
4.1. Hemodynamics of the whole cohort 
The systolic and diastolic blood pressure of the complete study group did not 
change significantly after PTA (systolic blood pressure baseline 152±25 mmHg, 
follow-up 149±21 mmHg, p=0.62; diastolic blood pressure baseline 80±13 mmHg, 
follow-up 76±9 mmHg, p=0.11). Heart rate also remained unchanged (baseline 
68±10/min, follow-up 69±11/min, p=0.70).  
There was a significant increase in ftPWV in the PTA-limb (baseline 7.6±2.5 
m/sec, follow-up 9.2±2.3 m/sec, p<0.0001) (Figure 2). Similarly, ABI improved 
significantly in the PTA-limb (baseline 0.67±0.32, follow-up 0.86±0.28, p<0.0001). In 
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the control-limb, ftPWV (baseline 9.1±2.7m/sec, follow-up 9.2±2.6 m/sec, p=0.334) 
remained unchanged as well as the ABI (baseline 0.92±0.24, follow-up 0.94±0.25, 
p=0.405). 
The aPWV (Mobil-O-Graph) remained unchanged (baseline 11.6±2.7 m/sec 
and follow-up 11.5±2.6 m/sec, p=0.410) (Figure 2). Likewise, there were no 
significant changes in cfPWV assessed by Vicorder in the control-limb (baseline 
8.6±2.5 m/sec, follow-up 8.4±2.2 m/sec, p=0.774) as well as in the PTA-limb 
(baseline 8.2±2.2 m/sec, follow-up 8.3±2 m/sec, p=0.116).  
PWV assessed as the carotid femoral travel time measured by the Vicorder 
device revealed lower velocities than aortic travel time by the Mobil-O-Graph. All p-
values were <0.001 for the comparison of aPWV (prior and postinterventional) and 
both cfPWV of the control- and PTA-limb. 
In the univariate regression analyses with PWV as the dependent and age as 
the independent variable cfPWV measured by Vicorder correlated significantly but 
not strongly with age in PTA- and control-limb (Figure 3). No significant correlations 
were found for age and ftPWV (control-limb at baseline and follow-up) nor in PTA-
limb at baseline. Mild but significant correlation resulted for age and ftPWV of PTA-
limb at follow-up (r=0.31, p<0.02).  
 
4.2 Iliac angioplasty subgroup 
When analysing the group of patients with obstructions in the iliac segment 
only, the results remained the same (Table 2). Revascularisation was associated with 
a significant increase of ftPWV (Baseline 7.5±2.6 m/sec, Follow-up 9±3 m/sec, 
p=0.011) and increase of the ABI (Baseline 0.69±0.27, Follow-up 0.85±0.27, 
p=0.021) in the PTA-limb. There was a non-significant increase in cfPWV in the PTA-
limb and control-limb periinterventional (PTA-limb baseline 7.8±1.9 m/sec, follow-up 
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8.4±1.7 m/sec, p=0.093; control-limb from 7.8±1.9 m/sec to 8.4±2.1 m/sec, p=0.198) 
(Figure 4. A). Aortic PWV remained unchanged after revascularization (Baseline 
10.9±2.9 m/sec, Follow-up 10.8±2.9 m/sec, p=0.448).  
When the iliac subgroup was analysed for occluded (n=3) and stenosed 
(n=15) vessels, there was a trend toward acceleration of cfPWV following 
revascularization in occluded iliac arteries by Vicorder (occlusions: cfPWV baseline 
7.0±2.7 m/s follow-up 8.6±1.4 m/s, p=0.18, stenosis: cfPWV baseline 8.0±1.6 m/s 
follow-up 8.3±1.7 m/s, p=0.27) (Figure 4. B).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
15 
5. Discussion 
 
This study evaluated the influence of PTA in patients with PAD on brachial 
derived aortic, carotid-femoral and femoral-tibial PWV. The main findings of the study 
is that femoro-tibial PWV and ABI of the treated limbs increased significantly 
following lower limb angioplasty, whereas the carotid-femoral and aortic PWV as well 
as all other hemodynamic parameters did not change. 
To the best of our knowledge, this is the first study that examined not only the 
effect of lower-limb revascularization on PWV of elastic (cfPWV and aPWV) and 
muscular arteries (ftPWV) but also used two different devices, the Vicorder and 
Mobil-O-Graph, for carotid-femoral and aortic PWV assessment in PAD patients.  
The assessment of PWV with the Mobil-O-Graph (aPWV) revealed higher 
velocities than the Vicorder (cfPWV). The latter is considered as the gold standard 
and current guidelines suggest a cut-off value of >10m/sec to diagnose arterial organ 
damage (AOD). With a mean cfPWV between 8.2 and 8.6 m/sec, the PAD subjects 
of our study would not fulfill the criteria for AOD in absence of an ABI assessment. 
When using the more recent tool for aortic PWV with a mean aPWV ranging between 
11.5- and 11.6m/sec, our PAD cohort would qualify for AOD. Despite this significant 
difference among the two methods, there were no periinterventional changes, except 
for a non-significant trend towards higher cfPWV when iliac obstructions were 
treated. The validation of the more recent Mobil-O-Graph is based on a comparison 
with Sphygmocor for central aortic blood pressure and with a cardiac magnetic 
resonance imaging for PWV showing agreement for both parameters, but direct 
comparison between Vicorder and Mobli-O-Graph in control subjects is lacking so far 
[20,21]. 
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 A potential shortcoming of the carotid-femoral PWV in PAD may be caused by 
aorto-iliac obstructions. One explanation for the lower cfPWV assessed by Vicorder 
in patients with PAD is that below the obstruction a decrease in distending pressure 
may develop [22]. Consequently, the femoralis pulse wave measured is flatter and 
the recorded systolic foot-point misrepresented in the oscillometric pulse wave. The 
transit time estimated with the foot-to-foot method may be underestimated leading to 
lower velocities in those segments. Brand et al. argued that decrease in distending 
pressure distal to arterial stenosis may effect a shift to less steep proportion of the 
exponential vascular pressure-volume relationship, with an attenuation of stiffness in 
these segments causing decreased cfPWV [22]. 
PAD represents an interesting subgroup of cardiovascular patients with the 
extent of atherosclerosis along the aortic and the peripheral arteries. Atherosclerosis 
is defined by thickening (atherosis) and stiffening (sclerosis) of the arterial wall [8]. 
Whereas the first is found in the inner layer (intima and media of the artery), the latter 
is confined to the media and adventitia of the arterial wall. Both structural changes 
may occur together or separate (i.e. mediacalcinosis) and have an impact on pulse 
wave propagation. ABI indicates severity of PAD and is an independent marker for 
prognosis [23]. With ageing, aortic stiffening increases aortic PWV (and pressure 
pulsatility) due to the loss in elastic properties mainly in the aorta and relates to 
reduced “Windkessel” effect [24]. In contrast, stiffening of muscular arteries occurs to 
a much lesser extent [24]. The relation between PWV and ABI in subjects with PAD 
is unclear [25]. PWV and ABI are both markers of vascular damage providing 
different information [26]. PWV is a marker of arterial stiffness, and ABI reflects 
obstruction or occlusion of peripheral arteries [25,26]. Accordingly, PWV is affected 
by stiffening in the aortic segment, whereas ABI remains unchanged [25]. 
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In Asian countries, arterial stiffness is frequently measured by brachial-ankle 
(ba)PWV since it is more comfortable and easier to assess than cfPWV [27,28]. In 
contrast to our study where we evaluated elastic and muscular artery velocities 
separately, the measurement of baPWV includes elastic and muscular arteries [27]. 
Therefore potential interactions between a loss of elasticity with increased PWV for 
the aortic segment and a decrease in PWV due to arterial obstructions in muscular 
arteries have to be taken into consideration. Due to the shorter pulse wave travel 
time, cfPWV tends to be lower than baPWV as reported in previous studies [27,29]. 
However, this difference is not only due to distance but also to travelling speed that 
varies in different parts of the arterial bed with lower velocities in elastic than in 
muscular arteries [27]. The arterial obstructions in PAD lead to underestimation of 
baPWV in patients with advanced PAD [26,29]. This is supported by an analysis of 
the association of baPWV and ABI on mortality in hemodialysis patients that found a 
weaker predictive value for mortality for baPWV than for ABI [26]. But when patients 
with advanced PAD (ABI<0.9) were excluded, baPWV restored its predictive power 
indicating the interference between the two vascular biomarkers mentioned above 
[26]. Furthermore, Yokoyama et al. found that baPWV is increased in diabetic 
patients, whereas it is decreased in the affected legs in diabetic patients with PAD 
[11]. In accordance with our study, they found that limb angioplasty increased both 
ABI and baPWV. In addition to their data, we analyzed PWV in three different modes 
as aortic, carotid-femoral and femoro-tibial and are able to show that PAD in relation 
to its severity is associated with a lower muscular arterial PWV that is at least 
attenuated in part after angioplasty. 
Calcification of the arteries of the lower extremities leads to a falsely increased 
ABI and results in underestimation of PAD severity [11,25,26]. Therefore, combined 
assessment of baPWV and ABI has been suggested [11,25]. The findings that 
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baPWV is a less powerful risk predictor than ABI  in patients on hemodialysis may be 
due to the fact that blood pressure highly varies in these patients with changes in 
systolic pressure influencing PWV [29,30]. Applying simply ABI < 0.9 for assessing 
PAD leads to an underestimation of prevalence of PAD in 20% of the subjects due to 
normal elevated ABI [25]. Thus, in patients with normal ABI, ba/(ft)PWV may help 
identifying high-risk individuals [26]. Therefore, our findings have clinical implication 
in that the assessment of ftPWV may supply complementary information of vascular 
damage. Based on previous research and our own results, we suggest that ftPWV 
may be an important adjunct to ABI that may be applied in primary as well as 
secondary prevention for estimations of the severity of PAD and to assess 
periinterventional changes of arteries with mediacalcinosis, which needs to be 
confirmed in future studies.  
The trend toward increase in cfPWV following PTA of occluded iliac vessels 
when assessed by the Vicorder device suggests that iliac obstruction has to be taken 
into account when cfPWV is assessed. The lack of significance is likely due to the 
low number of patients with iliac occlusion in our study. An alternative assessment of 
aortic pulse wave velocity is the brachial derived aortic PWV by the Mobil-O-Graph 
device, which turned out to be unaffected irrespective of vascular segments that were 
treated. Furthermore, the measurement with Mobil-O-Graph provided higher 
velocities than with the Vicorder. This might be due to the fact that PAD is usually 
restricted to the aorta and the lower limb arteries. The arteries of the upper 
extremities often remain unaffected. Therefore, assessment of PWV by Mobil-O-
Graph in patients with PAD should be preferred although this needs to be supported 
by furthers studies [11]. Another advantage of assessing PWV by Mobil-O-Graph is 
that the device is independent of the user, requires no training, can provide 
simultaneously 24-hour blood pressure and based on an averaged PWV may give 
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additional reliable information for cardiovascular risk [13]. There is limited information 
on the association of PWV and PAD. Catalano et al. examined arterial stiffness in 
PAD patients with the SphymoCor device and found that aortic PWV was higher in 
patients with PAD than in the control group [10]. Interestingly they found that PAD 
patients showed no correlation between PWV and age in contrast to the controls 
indicating the interference of atherosclerosis and PWV mentioned above [10]. In our 
study there was a weak but significant correlation between cfPWV and age. As 
expected, we found a strong and significant correlation for age and aPWV (baseline 
r=0.97 p<0.0001, follow-up r=0.96, p<0.0001) which is based on the device algorithm 
taken age into the calculation and therefore is of limited value.  
The limited number of subjects in this first study evaluating two devices, elastic 
and muscular arteries and the results of the iliac subgroup have to be considered 
with caution. It is quite likely, that in a larger cohort with iliac occlusions, the 
periinterventional changes of cfPWV would turn out to be significant for the treated 
limb. Further studies are needed to prove that and to substantiate the evidence that 
cfPWV may have to be considered with caution at least in the elderly population with 
a rather high prevalence of PAD. This goes in line with the methodological limitation 
of the Vicorder device in that aortic, iliac or femoral obstructions may reduce and 
delay the pressure wave with a femoral pressure waveform that is inaccurately 
sensed as reported by Van Bortel et al. [31]. Furthermore, our study included only 
Caucasian patients. Therefore, these findings have to be verified in other randomized 
studies with larger population with PAD. 
In conclusion, endovascular lower-extremity revascularization significantly 
increased PWV in the femoral-tibial segment indicating that moderate and severe 
PAD is associated with lower muscular arterial PWV. In contrast, aortic PWV derived 
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from the brachial artery remained unchanged. Whether carotid-femoral PWV is 
altered in presence of PAD needs to be verified in future studies.  
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7. Tables and Figures 
 
Table 1. Patient‘s characteristics (n=58)   
Age (years) 73.7 ±13 
Male gender, n (%) 32 (55.2) 
Height (cm) 168.7 ±10.5 
Weight (kg) 75.5±18.4 
Body-Mass-Index (kg/m²) 26.3±4.7 
Cardiovascular risk factors n (%) 
Arterial Hypertension 49 (84.5) 
Hyperlipidemia 29 (50) 
Diabetes mellitus 13 (22.4) 
Family history 14 (24.1) 
Smoker 
current 21 (36.2) 
former 15 (25.9) 
never 22 (37.9) 
Cardiovascular comorbidities n (%) 
Coronary artery disease 21 (36.2) 
Cerebrovascular disease 11 (19) 
Renal dysfunction 
GFR 50-69 
ml/min 
 
14 (24.1) 
GFR 30-49 
ml/min 
 
17 (29.3) 
GFR 15-30 
ml/min 
 
5 (8.6) 
GFR <15 ml/min 1 (1.7) 
Cardiovascular medication n (%) 
Aspirin 41 (70.7) 
Clopidogrel 10 (17.2) 
Phenprocoumon 7 (12.1) 
Statin 31 (53.4) 
ACE-I/AT-II-Antagonist 43 (74.1) 
Beta blocker 25 (43.1) 
Calcium channel blockers 19 (32.8) 
Diuretics 24 (41.4) 
Rutherford classification n (%) 
Category 2 11 (19) 
Category 3 22 (37.9) 
Category 4 8 (13.8) 
Category 5 17 (29.3) 
Data are mean (range or standard deviations) for quantitative variables and 
number (percentage) for categorical variables 
Creatinine clearance according to the Cockcroft- Gault equation 
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Table 2. Baseline Hemodynamic parameters of the treated iliac arteries   
 
     
  
Baseline Follow-up p 
     Pulse Wave Velocity (m/sec)* 
   
 
Brachial                     10.9±2.9 10.8±2.9 0.448 
     PWV-PTA-Limb (m/sec)** 
   
 
Carotid-femoral                 7.8±1.9 8.4±1.7 0.093 
 
Femoro-tibial                       7.5±2.6 9±3 0.011 
     PWV-Control-Limb (m/sec)** 
   
 
Carotid-femoral                7.8±1.9 8.4±2.1 0.198 
 
Femoro-tibial                 8.6±2.2 8.8±3 0.396 
     Ankle-Brachial Arterial Pressure Index 
   
 
PTA-Limb              0.69±0.27 0.85±0.27 0.021 
 
Control-Limb         0.87±0.21 0.93±0.22 0.315 
   
   Values refer either to subjects (n=16), to PTA- Limbs (n=18), or to Control- Limbs (n=14);  
PWV: Pulse wave velocity, *Mobil-O-Graph, **Vicorder 
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Included patients with PAD 
n= 63
Baseline assessment of
brachial PWV (Mobil-O-Graph)
and cf-/ft- PWV (Vicorder)
Excluded patients due to
invalid Mobil-O-Graph 
measurements
n=5
PTA patients n =58
Unilateral n =54
Bilateral n=4
Iliac ± infrainguinal
n=18
Stenosis n=15
Occluded n=3
Femoro-popliteal ± below the
knee
n=33
Stenosis n=18
Occluded n=15
Crural ± Below-the-knee
n=11
Stenosis n=6
Occluded n=5
Totally treated limbs
n=62
with totally treated segments
n=92
Fig. 1. Flow chart of included patients with peripheral arterial disease, treated limbs and vascular lesion. Obstruction 
characterstics refer to the proximal lesion treated.
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